Intradigm is a private biotechnology company focused on the discovery, development and delivery of novel targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. The company possesses a comprehensive RNAi therapeutic platform comprised of proprietary delivery technologies, potent siRNA sequences and innovative siRNA structural features. This platform is well protected by Intradigm’s strong intellectual property portfolio which includes a number of issued U.S. patents.
Â